secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q1 revenue $184M beats guidance; adjusted EBITDA $53.2M
--------------------------------------------------------------

- Revenue $184.0M exceeds guidance; adjusted EBITDA $53.2M (28.9% margin) also above range.
- Net loss $3.3M includes $25.5M stock-based comp; adjusted net income $29.5M (16.0% margin).
- Scott Wagner appointed Interim CEO; Trevor Bezdek remains Chairman; leadership aims to accelerate growth.
- Over 450,000 prescribers engaged via Provider Mode; over 7M consumers of prescription offerings.
- Operating cash flow $32.3M in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000095017023020003/0000950170-23-020003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000095017023020003/gdrx-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer